絞り込み

16548

広告

中国 仏技術採用の新型原発 世界初の営業運転

原子力発電所の建設を積極的に推し進めている中国で、フランスの技術を採用した新型の原発が世界で初めて営業運転を開始し、東京電力福島第一原子力発電所の事故を受けて、...

  1. スマブラ「灯火の星」セリフ・低予算版&カ...
  2. 企業活動の及ぼす環境影響を貨幣価値に換算...
  3. [企業] Axovant社 ガングリオシ...
  4. 月10冊を目標に読書をはじめてから気づい...

ニュース一覧

Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.

著者 Keller S , Zwingenberger G , Ebert K , Hasenauer J , Wasmuth J , Maier D , Haffner I , Schierle K , Weirich G , Luber B
Mol Oncol.2018 Jan 11 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (62view , 0users)

Full Text Sources

Miscellaneous

The molecular mechanism of action of the HER2-targeted antibody trastuzumab is only partially understood, and the direct effects of trastuzumab on the gastric cancer signaling network are unknown. In this study, we compared the molecular effect of trastuzumab and the HER kinase inhibitor afatinib on the receptor tyrosine kinase (RTK) network and the downstream-acting intracellular kinases in gastric cancer cell lines. The molecular effects of trastuzumab and afatinib on the phosphorylation of 49 RTKs and 43 intracellular kinase phosphorylation sites were investigated in three gastric cancer cell lines (NCI-N87, MKN1 and MKN7) using proteome profiling. To evaluate these effects, data were analyzed using mixed models and clustering. Moreover, proliferation assays were performed. Our comprehensive quantitative analysis of kinase activity in gastric cancer cell lines indicates that trastuzumab and afatinib selectively influenced the HER family RTKs. The effects of trastuzumab differed between cell lines, depending on the presence of activated HER2. The effects of trastuzumab monotherapy were not transduced to the intracellular kinase network. Afatinib alone or in combination with trastuzumab influenced HER kinases in all cell lines, that is, the effects of monotherapy and combination therapy were transduced to the intracellular kinase network. These results were confirmed by proliferation analysis. Additionally, the MET amplified cell line Hs746T was identified as afatinib non-responder. The dependence of the effect of trastuzumab on the presence of activated HER2 might explain the clinical non-response of some patients who are routinely tested for HER2 expression and gene amplification in the clinic but not for HER2 activation. The consistent effects of afatinib on HER RTKs and downstream kinase activation suggest that afatinib might be an effective candidate in the future treatment of gastric cancer patients irrespective of the presence of activated HER2. However, MET amplification should be taken into account as potential resistance factor.
PMID: 29325228 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード